Interview with the CEO


The Scrip magazine interviewed CEO Per Norlén at the 10th Annual Biotech Showcase Conference in January 2018.

Mike Ward, Global Director of Content, Informa Pharma Insight: ”Following a deal, worth potentially $700m plus, signed in 2015 with Johnson & Johnson’s Janssen Biotech, Swedish biotech Alligator Bioscience AB is well placed to drive its clinical pipeline. During Biotech Showcase, CEO Per Norlén outlined to Scrip the current status of the pipeline and its plans moving forward which includes having five clinical programs in place by the end of 2019.” Listen to the interview here.